Can Eli Lilly Sustain Its Obesity Momentum as Newer Players Emerge?

Key Takeaways LLY relies on its expanding obesity pipeline as more biotech challengers enter the market.GPCR's aleniglipron showed notable weight-loss data, adding pressure in the obesity space.LLY pushes orforglipron and retatrutide toward late-stage milestones to preserve obesity momentum.Eli Lilly and Company (LLY) is one of the two companies that dominate the booming cardiometabolic space, driven by its successful GLP-1 therapies — Mounjaro for diabetes and Zepbound for weight loss, both comprising the ...